Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer

In the phase III EMERALD trial, treatment with elacestrant significantly improved progression-free survival compared with investigator’s choice in patients with estrogen receptor-positive metastatic breast cancer that progressed on prior endocrine therapies.

Detalles Bibliográficos
Autor principal: Jacobson, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Conference Perspectives: Highlights from SABCS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963147/
https://www.ncbi.nlm.nih.gov/pubmed/35348779
http://dx.doi.org/10.1093/oncolo/oyac015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963147/
https://www.ncbi.nlm.nih.gov/pubmed/35348779
http://dx.doi.org/10.1093/oncolo/oyac015

Ejemplares similares